<DOC>
	<DOCNO>NCT02965118</DOCNO>
	<brief_summary>This phase III study investigate safety efficacy PAC-14028 cream Atopic Dermatitis patient .</brief_summary>
	<brief_title>CAPTAIN-AD : Clinical Study AmorePacific 's TRPV1 Antagonist Atopic Dermatitis</brief_title>
	<detailed_description>PAC-14028 cream 1.0 % placebo treat Mild Moderate Atopic Dermatitis patient twice daily 8 week .</detailed_description>
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<criteria>Male female patient age 12 70 year . Who diagnose Atopic Dermatitis accord Haniffin Rajka criterion . Whose affect TBSA 5 % 30 % , IGA score 2 ( mild ) 3 ( moderate ) . Who voluntarily agree participate study sign informed consent form . Who skin disease atopic dermatitis scar affect area affect study , determine study investigator . Who clinically significant medical history disease involve liver , kidney , neurological system , psychical disorder affect study result . Who use systemic steroid , antibiotic , immunosuppressant , receive phototherapy within 28 day study drug administration . Who use topical steroid , topical calcineurin inhibitor antibiotics treat atopic dermatitis within 14 day study drug administration . Who use expect inevitably use prohibited concomitant medication study . Women pregnant /breastfeeding , childbearing potential use available contraceptive . Who dose study medication within 30 day screen . Who determine ineligible study participation investigator reason .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>